Assessment of ocular hypotensive mechanisms and additivity of antiglaucoma drugs in humans.
D000287:Administration, Topical; D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D001082:Aqueous Humor / Q000378:metabolism*; D000068438:Brimonidine Tartrate; D003000:Clonidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D004357:Drug Synergism; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000494:pharmacology; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage / Q000494:pharmacology; D011810:Quinoxalines / Q000008:administration & dosage / Q000494:pharmacology*; D013999:Timolol / Q000008:administration & dosage / Q000494:pharmacology